Lot sizing in clinical trials manufacturing can save more than you think!
Manufacturing lot sizes are often considered as a given constraint when it comes to planning clinical trials manufacturing campaigns for active pharmaceutical ingredient/drug substance (API/DS) and drug product (DP) of most clinical programs.
During the planning of clinical trials manufacturing, the main scenarios that are tested involve challenging the timing of different production runs. Considered as a fixed quantity, lot sizes are only shifted in time in order to find what is perceived as the most efficient plan. However, this also leads to production quantities that may not be optimal given the fluctuations in clinical demand throughout the life of a program, the uncertain nature of clinical demand and the growing stability data.
An end-to-end view of the clinical supply chain can offer a better use of API/DS and production resources within clinical trials manufacturing.
Download our white paper to discover:
- Why is lot size such a critical parameter in clinical trials manufacturing?
Find out the 3 main reasons why optimizing lot sizes in clinical trials manufacturing plans can reveal savings and reduced drug waste.
- How optimizing lot sizes improves the clinical supply program
Through a case study from a top pharmaceutical company, find out how drug product lot sizes have been optimized and which measurable benefits it brought to the clinical supply program.
- How to achieve optimal lot sizing for clinical trials manufacturing
Learn how optimization software can provide an accurate view on the end-to-end clinical supply chain and enable data-driven decisions to achieve the best strategy for your clinical supply strategy.
Justin Gellezak
